Safety and pharmacokinetics of rituximab in combination with FAB chemotherapy in children and adolescents with Stage III/IV mature B-NHL and B-cell leukemia ± CNS disease: a Children's Oncology Group Report

被引：0
|
作者：
Barth, M. J. [1 ]
Goldman, S. [2 ]
Zhi, J. [3 ]
Smith, L. [4 ]
Harrison, L. [5 ]
Perkins, S. L. [6 ]
Shiramizu, B. [7 ]
Gross, T. [6 ,8 ]
Sanger, W. [4 ]
Cairo, M. S. [5 ,9 ,10 ,11 ,12 ]
机构：
[1] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[2] Med City Childrens Hosp, Div Pediat Hematol Oncol, Dallas, TX USA
[3] Hoffmann La Roche Inc, Nutley, NJ 07110 USA
[4] Univ Nebraska, Coll Publ Hlth, Dept Biostat, Omaha, NE 68182 USA
[5] New York Med Coll, Dept Pediat, Valhalla, NY 10595 USA
[6] Univ Utah, Dept Pathol, Salt Lake City, UT USA
[7] Univ Hawaii, Div Pediat Hematol Oncol, Honolulu, HI 96822 USA
[8] Ohio State Univ, Columbus, OH 43210 USA
[9] New York Med Coll, Dept Med, Valhalla, NY 10595 USA
[10] New York Med Coll, Dept Pathol, Valhalla, NY 10595 USA
[11] New York Med Coll, Dept Microbiol, Valhalla, NY 10595 USA
[12] New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2012年 / 159卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
40
引用
收藏
页码：23 / 23
页数：1
相关论文
共 50 条
  • [1] SAFETY AND PHARMACOKINETICS (PK) OF RITUXIMAB (R) IN COMBINATION WITH FAB CHEMOTHERAPY IN CHILDREN AND ADOLESCENTS (C+A) WITH STAGE III/IV MATURE B-NHL: A CHILDREN'S ONCOLOGY GROUP REPORT
    Barth, M. J.
    Goldman, S.
    Zhi, J.
    Smith, L.
    Perkins, S. L.
    Shiramizu, B.
    Gross, T.
    Sanger, W.
    Cairo, M. S.
    ANNALS OF ONCOLOGY, 2011, 22 : 112 - 112
  • [2] The Efficacy of Rasburicase and Rituximab Combined with FAB Chemotherapy in Children and Adolescents with Newly Diagnosed Stage III/IV, BM plus and CNS plus Mature B-NHL: A Children's Oncology Group Report
    Goldman, Stanton
    Galardy, Paul J.
    Smith, Lynette
    Perkins, Sherrie L.
    Shiramizu, Bruce
    Gross, Thomas
    Sanger, Warren G.
    Harrison, Lauren
    Cairo, Mitchell S.
    BLOOD, 2011, 118 (21) : 1161 - 1162
  • [3] Safety, kinetics, and outcome following rituximab (R) in combination with FAB chemotherapy in children and adolescents (C plus A) with stage III/IV (Group B) and BM plus /CNS plus (Group C) mature B-NHL: A Children's Oncology Group report.
    Cairo, M. S.
    Lynch, J. C.
    Harrison, L.
    Perkins, S. L.
    Shiramizu, B.
    Gross, T. G.
    Sanger, W.
    Goldman, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] OUTCOME AND PATTERNS OF FAILURE FOLLOWING COMBINED FAB CHEMOTHERAPY AND RITUXIMAB IN CHILDREN AND ADOLESCENTS WITH STAGE III/IV, BM+ AND/OR CNS+ MATURE B-NHL: A CHILDREN'S ONCOLOGY REPORT
    Goldman, S.
    Smith, L.
    Perkins, S. L.
    Shiramizu, B.
    Gross, T.
    Sanger, W.
    Harrison, L.
    Cairo, M. S.
    ANNALS OF ONCOLOGY, 2011, 22 : 176 - 176
  • [5] Safety, Efficacy and Rituximab Levels Following Chemoimmunotherapy (Rituximab plus FAB Chemotherapy) in Children and Adolescents with Mature B-Cell Non-Hodgkin Lymphoma (B-NHL): A Children's Oncology Group Report
    Cairo, Mitchell S.
    Lynch, James
    Harrison, Lauren
    van de Ven, Carmella
    Gross, Thomas
    Shiramizu, Bruce
    Sanger, Warren
    Perkins, Sherrie L.
    Goldman, Stanton
    BLOOD, 2008, 112 (11) : 310 - 310
  • [6] OUTCOME AND PHARMACOKINETIC (PK) ANALYSIS OF ADDING RITUXIMAB TO FAB CHEMOTHERAPY IN CHILDREN AND ADOLESCENTS WITH ADVANCED MATURE B-NHL/LEUKEMIA: A CHILDREN'S ONCOLOGY GROUP REPORT
    Goldman, Stan
    Smith, Lynette
    Perkins, Sherrie
    Shiramizu, Bruce
    Gross, Thomas
    Sanger, Warren
    Harrison, Lauren
    Cairo, Mitchell
    PEDIATRIC BLOOD & CANCER, 2011, 57 (05) : 737 - 738
  • [7] Outcome of advanced stage (III/IV) intermediate-risk patients with mature B-NHL using rituximab plus FAB group B4 chemotherapy: a Children's Oncology Group report
    Goldman, S.
    Smith, L.
    Anderson, J. R.
    Perkins, S.
    Harrison, L.
    Shiramizu, B.
    Sanger, W.
    Barth, M.
    Cairo, M. S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 159 : 24 - 24
  • [8] Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children’s Oncology Group report
    S Goldman
    L Smith
    J R Anderson
    S Perkins
    L Harrison
    M B Geyer
    T G Gross
    H Weinstein
    S Bergeron
    B Shiramizu
    W Sanger
    M Barth
    J Zhi
    M S Cairo
    Leukemia, 2013, 27 : 1174 - 1177
  • [9] Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report
    Goldman, S.
    Smith, L.
    Anderson, J. R.
    Perkins, S.
    Harrison, L.
    Geyer, M. B.
    Gross, T. G.
    Weinstein, H.
    Bergeron, S.
    Shiramizu, B.
    Sanger, W.
    Barth, M.
    Zhi, J.
    Cairo, M. S.
    LEUKEMIA, 2013, 27 (05) : 1174 - 1177
  • [10] Preliminary Results of the Addition of Rasburicase to the Reduction Cycle and Rituximab to the Induction and Consolidation Cycles of FAB Group C Chemotherapy in Children and Adolescents with Advanced Stage (Bone Marrow +/-CNS) Mature B-Cell Non-Hodgkin Lymphoma (B-NHL): A Children's Oncology Group Report
    Goldman, Stanton
    Lynch, James
    Harrison, Lauren
    Gross, Thomas
    Shiramizu, Bruce
    Sanger, Warren
    Perkins, Sherrie L.
    Cairo, Mitchell S.
    BLOOD, 2009, 114 (22) : 48 - 48
12345